Need for Desire Drugs Debated.

Manag Care

Published: February 2017

Some see a big market for medications for low libido in women. But sales of Addyi have been slow. Has a normal experience been unnecessarily medicalized? One of many factors in the debate is whether women#x02019;s sexual response tends to be more spontaneous or responsive.

Download full-text PDF

Source

Publication Analysis

Top Keywords

desire drugs
4
drugs debated
4
debated big
4
big market
4
market medications
4
medications low
4
low libido
4
libido women
4
women sales
4
sales addyi
4

Similar Publications

Article Synopsis
  • The demand for cosmetic procedures has surged, driven by people's desire for self-improvement, but many are unaware of the risks involved.
  • A study in the Madinah community surveyed 82 individuals, mainly young Saudi adults, to understand their awareness of cosmetic procedures and associated complications.
  • Although most participants recognized the existence of risks, a significant portion lacked detailed knowledge about specific complications, indicating the need for better education on the topic.
View Article and Find Full Text PDF

Society of Family Planning Clinical Recommendation: Medication management for early pregnancy loss.

Contraception

December 2024

Planned Parenthood South Atlantic, Raleigh, NC, USA and McLeod Regional Medical Center, Florence, SC, USA; University of Washington Department of Obstetrics and Gynecology, 1959 NE Pacific St, Box 356460, Seattle, WA 98005, USA; Pegasus Health Justice Center, Dallas, TX, 75207, USA; Washington University, St. Louis, MO, USA.

Early pregnancy loss (EPL), also known as miscarriage or spontaneous abortion, makes up 15-20% of all clinically recognized pregnancies. EPL is a broad term that includes intrauterine pregnancies (IUPs) with findings that suggest the pregnancy may not progress or definitely will not progress; pregnancies with a gestational sac (GS) in the lower endometrial cavity or endocervical canal in the process of expulsion; residual pregnancy tissue or persistent GS; and complete passage of the GS without residual tissue. This document addresses medication management of EPL in which the complete passage of the GS has not yet occurred, including pregnancies concerning for and diagnostic of EPL (sometimes called "missed abortion") and EPL in progress.

View Article and Find Full Text PDF

Objective: The new antiamyloid medications Lecanemab (Leqembi) and donanemab (Kisunla) are the first disease-modifying treatments for Alzheimer's disease (AD) to receive full FDA approval. However, some commentators question whether the drugs' benefits outweigh their risks, burdens, and costs to patients. This study assessed the perceived value of these medications by asking caregivers of persons with AD to compare them to a widely used intervention in AD management: home-based care.

View Article and Find Full Text PDF

Background: HIV disproportionately impacts people who experience incarceration. Incarceration represents an opportunity to engage in HIV prevention care for individuals who often experience a number of barriers accessing health services in the community. The development of evidence-based practices promoting pre-exposure prophylaxis for HIV prevention (PrEP) is crucial for ending the HIV epidemic within this highly marginalized population.

View Article and Find Full Text PDF

This study aims to investigate the effect and potential mechanism of Polygonati Rhizoma aqueous extract in protecting mice from gastric mucosal injury(stomach Yin deficiency). ICR mice were administrated with the mixture of pungent substance extract and alcohol by gavage once a day for 6 weeks to establish the mouse model of gastric mucosal injury with gastric Yin deficiency. The modeled mice were randomized into three groups of model and Polygonati Rhizoma aqueous extract administrated at 0.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!